New at Santen

Dr Naveed Shams has been appointed as the new vice president of clinical affairs at Santen Pharmaceutical Co., Ltd.

“Dr. Shams is a highly respected scientist and brings an expertise in developing and commercializing ophthalmic drugs, ” said Santen Chief Operating Officer, Aki Tsujimura. “His insights in this area will prove invaluable, as he has a wealth of experience in basic research, drug discovery, ophthalmic formulations, and drug delivery. ”

Dr Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his Ph.D. from the University of South Carolina in microbiology and immunology. He completed fellowships in cornea and external diseases at Harvard Medical School and histocompatibility and immunogenetics at Massachusetts General Hospital. He was formerly on faculty at Schepen's Eye Research Institute and the Department of Ophthalmology at Harvard Medical School.

His career in drug development is extensive and he has played a role in bringing Zaditen, Rescula and Lucentis to market.